[Pomalidomide for relapsed and refractory myeloma]
Mengarelli C, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32017000284
Spanish
Authors' recommendations:
Low-quality evidence suggests that polalidomide treatment for patients with refractory or relapsed multiple myeloma after treatment with lenalidomide and bortezomib might improve disease remission rates.
In general, clinical practice guidelines and some United States private health sponsors suggest using pomalidomide in patients with refractory or relapsed multiple myeloma as third-line therapy after using lenalidomide and bortezomib.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Angiogenesis Inhibitors
- Multiple Myeloma
- Thalidomide
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.